Survodutide
Metabolic Health · GLP-1/glucagon agonist (dual)
Tier B
What this is
Boehringer Ingelheim/Zealand Pharma. SYNCHRONIZE-1 (no T2D, n=725) and SYNCHRONIZE-2 (with T2D, n=752) Phase 3 trials enrolling — both 76-week trials with primary endpoint % body weight change. Phase 2 (Le Roux 2024 Lancet) showed up to 19% weight loss. Particular promise for metabolic-associated steatotic liver disease (MASLD/NAFLD) due to glucagon's hepatic fat oxidation effects.
Mechanism
Dual GLP-1 receptor and glucagon receptor agonist; glucagon arm increases energy expenditure and hepatic fat oxidation; particular interest for MASLD/metabolic liver disease
Dose & route
3.6 or 6.0 mg SC weekly (Phase 3 doses); titrated
Citations
- https://doi.org/10.1111/dom.70196
- https://doi.org/10.1111/dom.70263
- https://doi.org/10.1016/j.conctc.2026.101611
- https://doi.org/10.1186/s12933-026-03140-0
- https://doi.org/10.1007/s11695-026-08692-4
- https://doi.org/10.3390/livers6030035
Links go to the source. If a link is dead or you want something re-checked, let me know.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.